A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
about
Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer TreatmentEfficiently editing the vaccinia virus genome by using the CRISPR-Cas9 system.Trial watch: Naked and vectored DNA-based anticancer vaccinesAssociation between MTHFR A1298C polymorphism and male infertility: A meta-analysis.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.Management Options for Biochemically Recurrent Prostate Cancer.Oncolytic Viruses-Natural and Genetically Engineered Cancer Immunotherapies.Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer.Therapeutic cancer vaccines.Therapy: An immune one–two punch
P2860
Q33718182-21DAB63E-FDF1-4FED-B8CA-7ECDD21E7C06Q35488657-F1B64C67-1D34-492C-8BFA-E68239A68211Q35798986-1DFA6A4B-2093-4410-B4B9-E41EA807C0C9Q36342755-9CAB4AFE-47CE-4C74-B07D-820D7E48C9EAQ37518336-986E96FA-21A0-47FC-9221-F9DFDA71DED0Q38600417-4D485056-7A02-4CAC-9F9C-0DC7548BBDFAQ38691937-58DE923C-4343-4F1F-B69A-ECA372FC1E24Q41684403-030E24B6-FEDC-4459-BC98-7AC2A3644416Q49835554-74CFE74D-036E-4A25-94B7-B29649DCD0AFQ50988785-528D8786-3342-4425-9E07-84CE66EEED5EQ74441187-2763B430-EBCD-495C-96A0-43EA0DDF975D
P2860
A national multicenter phase 2 study of prostate-specific antigen (PSA) pox virus vaccine with sequential androgen ablation therapy in patients with PSA progression: ECOG 9802.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@ast
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@en
type
label
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@ast
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@en
prefLabel
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@ast
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@en
P2093
P2860
P1433
P1476
A national multicenter phase 2 ...... th PSA progression: ECOG 9802.
@en
P2093
Edmund C Lattime
Glenn J Bubley
James L Gulley
Lisa H Butterfield
Mark N Stein
Michael A Carducci
Noah M Hahn
Philip M Arlen
Robert S DiPaola
Yu-Hui Chen
P2860
P304
P356
10.1016/J.EURURO.2014.12.010
P407
P577
2014-12-01T00:00:00Z